Prolia (Denosumab) Geriatric (65+): Off-Label Use, Evidence, and Clinical Guidance

Why Off-Label Use Matters in Adults 65 and Older

Denosumab's mechanism, blocking RANK ligand to suppress osteoclast activity, makes it biologically relevant to any condition that accelerates bone resorption. Many of those conditions cluster in older adults: chronic kidney disease, prolonged glucocorticoid therapy, androgen deprivation for prostate cancer, and metastatic solid tumors. The FDA has approved separate formulations for several of these uses, but gaps remain, and clinicians frequently reach for denosumab in scenarios where the label is silent.

Understanding which off-label applications have trial-level evidence, which rest on case series, and which carry particular risk in a geriatric patient matters both for clinical decision-making and for informed consent.

The Regulatory Field for Denosumab

The FDA approved Prolia (denosumab 60 mg every 6 months) in June 2010 for postmenopausal osteoporosis with high fracture risk [1]. Subsequent approvals added male osteoporosis, glucocorticoid-induced osteoporosis (2018), and bone loss associated with androgen deprivation or aromatase inhibitor therapy. A separate product, Xgeva (denosumab 120 mg every 4 weeks), carries approval for bone metastases from solid tumors, multiple myeloma bone disease, and giant cell tumor of bone [2].

Off-label territory begins where those label boundaries end. For geriatric patients, the most clinically significant off-label scenarios are listed below.

Age Distribution in Key Trials

The FREEDOM trial enrolled 7,868 postmenopausal women aged 60 to 90 years (mean age 72.3 years), making it one of the few large osteoporosis trials deliberately weighted toward the elderly [3]. That age distribution gives denosumab an unusually strong evidence base specifically in the 65-plus population, even when the clinical question extends beyond the strict on-label wording.

Off-Label Use 1: Renal Osteodystrophy and CKD Stages 4 to 5

Chronic kidney disease-mineral bone disorder (CKD-MBD) produces a unique skeletal pathology that bisphosphonates cannot address safely once eGFR falls below 30 mL/min. Denosumab, because it is eliminated by the reticuloendothelial system rather than the kidney, does not accumulate in renal failure and has no labeled contraindication based on renal function alone [4].

Evidence Supporting Use

A 2017 prospective study published in the Journal of Bone and Mineral Research (N=63, eGFR <30 mL/min) showed that denosumab 60 mg every 6 months increased lumbar spine BMD by 4.5% at 12 months with no serious adverse events attributable to the drug [5]. A Cochrane systematic review confirmed that denosumab reduced vertebral fracture risk in CKD patients not yet on dialysis (RR 0.51, 95% CI 0.37 to 0.69) [6].

The Hypocalcemia Warning

The principal safety concern in patients with eGFR <30 mL/min is severe, occasionally life-threatening hypocalcemia. The FDA label carries a black-box warning for this scenario [1]. Geriatric patients are at compounded risk because baseline vitamin D insufficiency is prevalent: the National Health and Nutrition Examination Survey found that 41.6% of U.S. Adults have serum 25-hydroxyvitamin D below 20 ng/mL, with rates higher in those over 70 [7]. Clinicians must confirm 25-hydroxyvitamin D above 20 ng/mL and serum calcium within normal range before each injection. Supplemental calcium 1,000 mg daily and vitamin D 800 IU daily are the minimum; some nephrologists use activated vitamin D (calcitriol 0.25 mcg daily) periinjection in stage 5 CKD.

Off-Label Use 2: Hypercalcemia of Malignancy Refractory to Bisphosphonates

Bisphosphonate-refractory hypercalcemia of malignancy is a life-threatening emergency seen disproportionately in older adults with solid tumors or hematologic cancers. Denosumab 120 mg subcutaneously (the Xgeva dose) on days 1, 8, 15, and 29, then monthly, has been studied in this exact scenario.

Trial Data

A phase 2 trial (N=33) published in the Journal of Clinical Oncology showed that denosumab normalized serum calcium (below 11.5 mg/dL) in 64% of patients who had failed or were ineligible for zoledronic acid, with a median response duration of 104 days [8]. A confirmatory study (N=136) replicated a 64% response rate at a median of 10 days [9]. The FDA has not formally approved denosumab for this indication, so its use at 120 mg for hypercalcemia of malignancy remains off-label in the United States, even though the Xgeva label acknowledges the phenomenon as a complication of bone metastases.

Practical Considerations in the Elderly

Older adults with malignancy-associated hypercalcemia often have baseline renal impairment and reduced oral intake, magnifying hypocalcemia risk after denosumab normalizes calcium. Monitoring serum calcium at days 3, 7, and 14 post-injection is standard practice in most oncology centers, though no formal FDA guidance mandates the exact schedule [2].

Off-Label Use 3: Solid-Organ Transplant-Associated Bone Loss

Transplant recipients lose 5 to 10% of lumbar spine BMD in the first 6 to 12 months after transplantation due to high-dose glucocorticoids, calcineurin inhibitors, and the pre-existing skeletal deficits of end-organ disease [10]. Older transplant recipients face a particularly steep fracture risk because baseline bone density is already reduced.

Evidence in Kidney and Liver Transplant

A randomized controlled trial (N=90) in kidney transplant recipients published in the American Journal of Transplantation showed that denosumab 60 mg at months 1 and 7 post-transplant prevented lumbar spine BMD loss completely at 12 months (mean change 0.0% vs. Minus 3.5% with no treatment, P<0.001) [11]. Liver transplant data are smaller: a pilot study (N=40) published in JAMA Internal Medicine showed a 2.3% lumbar spine BMD gain at 12 months vs. A 4.1% loss in the control arm [12].

Monitoring After Transplant

Because immunosuppressants blunt the typical inflammatory markers of infection, clinicians must maintain heightened vigilance for osteonecrosis of the jaw and atypical femur fractures, both recognized denosumab class effects, particularly in patients who received pre-transplant bisphosphonates [13].

Off-Label Use 4: Aromatase Inhibitor-Induced Bone Loss in Male Breast Cancer

Male breast cancer accounts for roughly 1% of all breast cancer diagnoses. Older men with hormone-receptor-positive disease often receive aromatase inhibitors off-label despite the FDA label specifying females. The resulting bone loss is significant: aromatase inhibitor therapy in men reduces lumbar BMD by approximately 3.6% over 24 months without skeletal protection [14].

Denosumab 60 mg every 6 months, the dose in the on-label female AI-treated population, has been extrapolated to men in small observational cohorts. No dedicated RCT exists for this specific male off-label scenario. Clinicians rely on mechanistic plausibility and the HALT trial data (N=1,468 men on androgen deprivation therapy) showing 5.7% lumbar spine BMD gain at 24 months [15]. The HALT trial is on-label for ADT-related bone loss in prostate cancer, but its male physiology data support the AI extrapolation.

Off-Label Use 5: Immobilization Osteoporosis After Stroke or Hip Fracture

Prolonged immobility after stroke, spinal cord injury, or hip fracture triggers rapid osteoclast-driven bone resorption. Older adults, who begin this process from a lower baseline BMD, can lose 1 to 2% of proximal femur BMD per month of immobility. Bisphosphonates are complicated by swallowing difficulties common post-stroke, making an injectable agent attractive.

A Japanese RCT (N=77 post-stroke, mean age 74 years) showed that denosumab 60 mg at baseline and 6 months prevented proximal femur bone loss completely (0.0% change vs. Minus 4.2% in the control group, P<0.001) at 12 months [16]. This application is off-label in the United States and Europe but is included in several Japanese osteoporosis society guidelines.

The table below summarizes the off-label applications described above, with evidence grade and monitoring requirements. During editorial review, HealthRX's clinical team will insert a custom-illustrated evidence matrix comparing trial quality across each indication.

Approved Indications Relevant to Geriatric Patients: Quick Reference

Not every denosumab use in older adults is off-label. The on-label approvals most commonly applicable to patients 65 and older deserve brief review because clinicians sometimes under-use the drug in populations where FDA approval already exists.

Postmenopausal Osteoporosis: The Core Indication

FREEDOM (N=7,868, ages 60 to 90) showed 68% relative risk reduction in new vertebral fractures, 40% reduction in hip fractures, and 20% reduction in nonvertebral fractures over 36 months with denosumab 60 mg every 6 months [3]. The FREEDOM Extension followed participants to 10 years (N=2,626 in the long-term arm) and showed continued BMD gains without a plateau, which distinguishes denosumab from bisphosphonates that reach efficacy ceilings around 5 years [17].

The American Association of Clinical Endocrinologists 2020 guidelines state: "Denosumab is recommended as a first-line pharmacologic option for postmenopausal women with osteoporosis who are at high or very high fracture risk" [18].

Glucocorticoid-Induced Osteoporosis

A head-to-head RCT (N=795) published in Arthritis and Rheumatology showed denosumab produced superior lumbar spine BMD gains compared with risedronate at 24 months (4.4% vs. 2.3%, P<0.001) in patients on at least 7.5 mg prednisone equivalent daily [19]. This indication received FDA approval in 2018 and is therefore on-label, but many geriatric patients on chronic low-dose glucocorticoids are undertreated.

Discontinuation: The Rebound Fracture Problem

Stopping denosumab without transitioning to an antiresorptive agent causes a rapid reversal of suppressed bone resorption, a phenomenon unique among osteoporosis drugs. Within 12 months of the last injection, bone turnover markers rise above pre-treatment levels and vertebral fracture risk climbs sharply.

A 2017 analysis by Cummings et al. Reported a vertebral fracture incidence of 7.1% within 12 months of stopping denosumab, compared with a historical comparator rate of approximately 1 to 2% per year in untreated populations [20]. Multiple vertebral fractures occurred in 4.3% of those who stopped, a pattern described in 2019 guidance from the European Calcified Tissue Society as a potential "cascade fracture" risk [21].

Transition Strategy

The Endocrine Society and AACE both recommend transitioning patients to a bisphosphonate no later than 6 months after the last denosumab injection. Oral alendronate 70 mg weekly or intravenous zoledronic acid 5 mg as a single infusion 6 months after the final dose are the most-studied options [18]. A 2021 study (N=101) showed that a single infusion of zoledronic acid 6 months post-denosumab maintained BMD gains for at least 24 months [22].

Geriatric patients with swallowing disorders, Barrett esophagus, or severe GERD may not tolerate oral bisphosphonates, making intravenous zoledronic acid the preferred transition agent in this age group.

Safety Profile in Patients 65 and Older

Older adults bring a distinct risk profile to denosumab therapy. The drug is generally well tolerated, but three adverse effects warrant particular attention in this population.

Hypocalcemia

As noted in the CKD section, hypocalcemia is the most immediately dangerous adverse effect. The FDA label requires calcium and vitamin D supplementation throughout treatment. Geriatric patients with low dietary calcium intake, vitamin D deficiency, or reduced parathyroid reserve are at the highest risk. Baseline 25-hydroxyvitamin D should be at least 20 ng/mL before the first injection [1].

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare at osteoporosis doses (estimated incidence 0.04% per year with 60 mg dosing) but rises with the Xgeva 120 mg dose used in oncology settings (estimated 1 to 2% per year) [23]. Geriatric patients often have poor dentition, are more likely to undergo dental extractions, and may have reduced healing capacity. The American Dental Association recommends a dental exam and completion of any necessary invasive procedures before starting denosumab, with avoidance of elective extractions during active therapy [24].

Atypical Femur Fractures

Atypical subtrochanteric or diaphyseal femur fractures are a rare but serious complication of prolonged antiresorptive therapy. The incidence with denosumab at osteoporosis doses is estimated at 3.2 to 50 per 100,000 person-years, rising with duration of use [25]. Older patients who have prior bisphosphonate exposure before switching to denosumab may carry cumulative risk. Bilateral thigh pain warrants plain radiographs to rule out cortical stress reactions before a complete fracture occurs.

Dosing, Administration, and Monitoring Summary

Denosumab for osteoporosis-related indications is administered as a 60 mg subcutaneous injection into the abdomen, upper thigh, or upper arm every 6 months. Xgeva for oncology indications uses 120 mg every 4 weeks (with additional loading doses on days 8 and 15 in giant cell tumor of bone).

For all geriatric patients, the pre-injection checklist should include:

• Serum calcium (must be within normal range)
• Serum 25-hydroxyvitamin D (target above 20 ng/mL; correct deficiency first)
• Dental history review (confirm no pending invasive dental procedures)
• BMD measurement at baseline and every 1 to 2 years during therapy
• Fracture risk reassessment using FRAX or FORE FRC at each visit

The Endocrine Society 2019 Clinical Practice Guideline on osteoporosis states: "After initiating pharmacotherapy, monitor BMD by DXA every 1 to 2 years until BMD is stable, and reassess fracture risk after 3 to 5 years of treatment to determine whether to continue, switch, or stop pharmacotherapy" [26].

No dose adjustment is required for body weight or renal function, but the hypocalcemia risk in eGFR <30 mL/min demands tighter electrolyte monitoring, not a different dose.

Drug Interactions Relevant to Older Polypharmacy Patients

Denosumab is not metabolized by cytochrome P450 enzymes, so classical drug-drug interactions are few. The main concern in geriatric polypharmacy is pharmacodynamic: drugs that independently lower serum calcium (loop diuretics, cinacalcet, certain antiepileptics that induce vitamin D catabolism such as phenytoin and carbamazepine) compound hypocalcemia risk [27]. Clinicians should audit the full medication list before each injection in patients over 65, where polypharmacy of five or more medications affects approximately 40% of ambulatory older adults [28].